Related Experiment Video
Updated: Dec 2, 2025
09:58
Lipidomics and Transcriptomics in Neurological Diseases
Published on: March 18, 2022
3.8K
Lipid-lowering Drugs and Neurocognitive Function: A Systematic Review
Georgios Kyriakos1, Lourdes Victoria Quiles-SÁnchez2, Evangelos Diamantis3
1Seccion de Endocrinologia y Nutrition, Hospital General Universitario Santa Lucia, Cartagena, Spain.
In Vivo (Athens, Greece)
|November 4, 2020
Summary
Lipid-lowering drugs, including statins, do not appear to significantly impact neurocognitive function in patients with cardiovascular conditions. Further research is recommended to confirm these findings on cognitive function.
Area of Science:
- Neuroscience
- Pharmacology
- Cardiology
Background:
- Lipid-lowering drugs are widely used for cardiovascular disease management.
- Concerns exist regarding their potential impact on neurocognitive function.
- Evidence on the neurocognitive effects of these agents requires updated synthesis.
Purpose of the Study:
- To review the latest clinical trial evidence on the neurocognitive effects of lipid-lowering drugs.
- To synthesize findings from recent randomized controlled trials.
Main Methods:
- Systematic literature search from 2015-2020 in PubMed, EMBASE, and Cochrane databases.
- Adherence to Preferred Reporting Items for Systematic reviews and Meta-Analyses (PRISMA) guidelines.
- Inclusion of randomized trials investigating cholesterol, lipid-lowering drugs, statins, and cognitive function.
Main Results:
- Eleven randomized trials met the inclusion criteria.
- Trials involved patients with cardiovascular conditions like coronary heart disease and hypercholesterolemia.
- Investigated agents included evolocumab, alirocumab, statins, ezetimibe, and placebo.
Conclusions:
- Current evidence suggests lipid-lowering drugs have no significant effect on neurocognitive function.
- Further research specifically targeting neurocognitive outcomes is warranted.
Related Concept Videos
01:30Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists
387
Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function.
387
01:22Alzheimer's Disease: Treatment
617
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
617
01:20Lipid-Lowering Drugs: Statins and Miscellaneous Agents
1.2K
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
1.2K
01:26Atherosclerosis III: Management
212
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
212
01:26Alzheimer's Disease: Overview
1.3K
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
1.3K
01:08Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment
95
Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
95